Outlook Therapeutics Stock (NASDAQ:OTLK)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$1.39

52W Range

$0.87 - $12.85

50D Avg

$4.31

200D Avg

$6.77

Market Cap

$34.06M

Avg Vol (3M)

$1.65M

Beta

0.63

Div Yield

-

OTLK Company Profile


Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

24

IPO Date

Jun 14, 2016

Website

OTLK Performance


OTLK Financial Summary


Sep 23Sep 22Sep 21
Revenue---
Operating Income$-53.13T$-63.07M$-51.73M
Net Income$-58.98T$-66.05M$-53.16M
EBITDA$-53.13T$-62.91M$-51.77M
Basic EPS$-0.24$-0.31$-0.35
Diluted EPS$-0.24$-0.31$-0.35

Fiscal year ends in Sep 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Aug 14, 24 | 12:02 PM
Q2 24May 16, 24 | 2:35 PM

Peer Comparison


TickerCompany
RVPHReviva Pharmaceuticals Holdings, Inc.
DAWNDay One Biopharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.
CKPTCheckpoint Therapeutics, Inc.
FBIOFortress Biotech, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
SLSSELLAS Life Sciences Group, Inc.
KODKodiak Sciences Inc.
MBIOMustang Bio, Inc.
HRTXHeron Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
EYENEyenovia, Inc.
CDTXCidara Therapeutics, Inc.